¼¼°èÀÇ ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀº ¾Æ¿ô¼Ò½Ì µ¿ÇâÀÇ Áõ°¡¸¦ ¹è°æÀ¸·Î 2024-2032³â 11%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î »ý°¢µË´Ï´Ù.
Á¦¾à»çµéÀº ºñ¿ë Àý°¨°ú ÇÙ½É ¾÷¹«¿¡ ÁýÁßÇϱâ À§ÇØ ¹é½Å Á¦Á¶ÀÇ ¿ÜÁÖȸ¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀÌ ÇÙ½É ¿ª·®¿¡ ÁýÁßÇÏ°í ºñ¿ë È¿À²¼ºÀ» Ãß±¸ÇÔ¿¡ µû¶ó ¹é½Å Á¦Á¶¸¦ Àü¹® ¾Æ¿ô¼Ò½Ì ¾÷ü¿¡ ¸Ã±â´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ¾Æ¿ô¼Ò½ÌÀ» ÅëÇØ ±â¾÷Àº °ªºñ½Ñ ÀÎÇÁ¶ó¿¡ ÅõÀÚÇÏÁö ¾Ê°íµµ ÷´Ü ±â¼ú°ú Àü¹® Áö½ÄÀ» Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼ÀÇ ¹è°æ¿¡´Â È®À强, À¯¿¬¼º, »õ·Î¿î ¹é½Å ½ÃÀå Ãâ½Ã ½Ã°£ ´ÜÃà¿¡ ´ëÇÑ ¿ä±¸°¡ ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î 2024³â 5¿ù, ¼¼°èÀûÀÎ Á¦¾àȸ»ç »ç³ëÇÇ´Â ÇÁ¶û½º³» 3°÷ÀÇ ¹ÙÀÌ¿À »ý»ê ´É·ÂÀ» È®´ëÇϱâ À§ÇØ 10¾ï À¯·Î(10¾ï 8,000¸¸ ´Þ·¯)¸¦ ÃʰúÇÏ´Â ´ë±Ô¸ð ÅõÀÚ¸¦ ¹ßÇ¥Çß½À´Ï´Ù. À̹ø ÅõÀÚ´Â ÇÁ¶û½º¿Í EUÀÇ ¿ÜºÎ Á¦Á¶¿ø ÀÇÁ¸µµ¸¦ ³·Ãß±â À§ÇÑ 35¾ï À¯·Î ±Ô¸ðÀÇ ÇÁ·Î±×·¥ÀÇ ÀÏȯÀÔ´Ï´Ù. COVID-19 ÆÒµ¥¹Í ÀÌÈÄ ÁÖ¸ñ¹Þ°ÔµÈ EUÀÇ °Ç° ÁÖ±Ç °³³ä¿¡ µû¶ó °ø±Þ¸ÁÀÇ ¾ÈÀü°ú ź·Â¼ºÀ» °ÈÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, Á¦¾à ½Ã½ºÅÛ °È, ¹é½Å ¹× ÀÇ·á Á¦Ç° Á¦Á¶ ¿ª·® °È, À§Çù °¨Áö ¹× ´ëÀÀ ¸ÞÄ¿´ÏÁò °³¼±¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. À§Çù °¨Áö ¹× ´ëÀÀ ¸ÞÄ¿´ÏÁò °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.
¶ÇÇÑ ¼öŹÁ¦Á¶¾÷ü´Â ±ÔÁ¦ Áؼö¿Í ǰÁú º¸ÁõÀ» Á¦°øÇÔÀ¸·Î½á È®´ëµÇ´Â ¹é½Å ½ÃÀå¿¡¼ ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡°¥ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.
ºÒȰ¼ºÈ ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀº ´Ù¾çÇÑ °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ½Å·ÚÇÒ ¼ö ÀÖ°í ¾ÈÀüÇÑ ¹é½ÅÀÇ Çʿ伺¿¡ ÈûÀÔ¾î 2024-2032³â °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÒȰ¼ºÈ ¹é½ÅÀº »ç¸êµÈ º´¿øÃ¼¸¦ »ç¿ëÇÏ¿© ¸é¿ª ¹ÝÀÀÀ» ÀÚ±ØÇÏ´Â ¹é½ÅÀ¸·Î, ¾àµ¶¼º »ý¹é½ÅÀÌ ÀûÇÕÇÏÁö ¾ÊÀº Áúº´À» ¿¹¹æÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. Á¦Á¶ ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² Àü ¼¼°è¿¡¼ °Ç°¿¡ ´ëÇÑ ¿ì·Á¿Í °¨¿°º´ ¹ß»ýÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àü¹®Àû Á¦Á¶ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °íǰÁúÀÇ ¾ÈÁ¤ÀûÀÎ ¹é½Å »ý»ê¿¡ ´ëÇÑ ±ÔÁ¦ ¿ä°ÇÀÌ ºÒȰ¼ºÈ ¹é½Å À§Å¹ ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
ÀÓ»ó ºÐ¾ß´Â 2032³â±îÁö Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÓ»ó ±Ô¸ðÀÇ ¹é½Å À§Å¹ »ý»ê¿¡ ´ëÇÑ ¼ö¿ä´Â ¹é½Å °³¹ß °úÁ¤¿¡¼ È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ Á¦Á¶ÀÇ Çʿ伺¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀÌ ÁøÇàµÊ¿¡ µû¶ó Á¦¾àȸ»ç´Â ½ÃÇè°ú Æò°¡¸¦ À§ÇØ ¹é½ÅÀ» ´ë·® »ý»êÇÒ ¼ö ÀÖ´Â Àü¹® Á¦Á¶½Ã¼³ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¾Æ¿ô¼Ò½Ì ¾÷ü´Â ÇÊ¿äÇÑ Àü¹® Áö½Ä, ±â¼ú, À¯¿¬¼ºÀ» Á¦°øÇÏ°í ±ÔÁ¦ Ç¥ÁØÀ» ÁؼöÇÏ¸é¼ ´Ù¾çÇÑ ±Ô¸ðÀÇ Á¦Á¶¿¡ ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÀÛ¾÷À» ¾Æ¿ô¼Ò½ÌÇÏ¸é °³¹ß ÀÏÁ¤À» °£¼ÒÈÇÏ°í ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖÀ¸¸ç, Àüü ÇÁ·ÎÁ§Æ®ÀÇ È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.
À¯·´ÀÇ ¹é½Å ¼öŹÁ¦Á¶ ½ÃÀåÀº 2024-2032³â Àü¹®ÀûÀÎ Á¦Á¶ ´É·ÂÀ» ¿ä±¸ÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØ ¶§¹®¿¡ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í Á¦Á¶ ±â¼ú ¹ßÀüµµ ÇѸòÀ» Çϰí ÀÖ½À´Ï´Ù. À¯·´Àº EU ¿ª¿Ü »ý»ê¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀ̰í, ƯÈ÷ ÆÒµ¥¹Í ÀÌÈÄ °ø±Þ¸Á º¹¿ø·ÂÀ» °ÈÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖÀ¸¸ç, ÀÌ´Â ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È®Àå °¡´ÉÇÑ Á¦Á¶ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺°ú ÇÔ²² ¹Î°ü Çù·Â Áõ°¡´Â ÀÌ Áö¿ªÀÇ ¼öŹÁ¦Á¶ ½ÃÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Global Vaccine Contract Manufacturing Market will depict 11% CAGR between 2024 and 2032, driven by the rising outsourcing trends. Pharmaceutical companies increasingly outsource vaccine production to reduce costs and focus on core activities. As pharmaceutical companies increasingly focus on core competencies and seek cost efficiencies, they turn to specialized contract manufacturers to handle vaccine production. Outsourcing allows companies to leverage advanced technologies and expertise without investing in costly infrastructure. This trend is driven by the need for scalability, flexibility, and accelerated time-to-market for new vaccines.
For instance, in May 2024, Sanofi, a leading global pharmaceutical company, announced a major investment exceeding €1 billion ($1.08 billion) to expand bioproduction capacity at three sites in France. This investment is part of a broader €3.5 billion program aimed at reducing France's and the EU's reliance on external manufacturing sources. The initiative seeks to enhance supply chain security and resilience, aligning with the EU's health sovereignty concept. This concept, which gained prominence after the COVID-19 pandemic, focuses on strengthening pharmaceutical systems, manufacturing capacities for vaccines and medical products, and improving threat detection and response mechanisms.
In addition, contract manufacturers offer regulatory compliance and quality assurance, further boosting their appeal in the expanding vaccine market.
The overall vaccine contract manufacturing industry is categorized based on vaccine type, scale of operation, service, product type, application, end-user, and region.
The inactivated vaccine contract manufacturing market will drive commendable gains over 2024-2032, propelled by the need for reliable and safe vaccines against various infectious diseases. Inactivated vaccines, which use killed pathogens to stimulate immune responses, are crucial for preventing diseases where live attenuated vaccines are not suitable. Advances in production technology, coupled with rising global health concerns and outbreaks, drive the need for specialized manufacturing. Additionally, regulatory requirements for high-quality, consistent vaccine production further boost the demand for inactivated vaccine contract services.
The clinical segment will capture a substantial market share by 2032. The demand for vaccine contract manufacturing at a clinical scale is stimulated by the need for efficient and scalable production during vaccine development. As clinical trials progress, pharmaceutical companies require specialized manufacturing facilities to produce vaccines in large quantities for testing and evaluation. Contract manufacturers offer the necessary expertise, technology, and flexibility to handle varying scales of production while ensuring compliance with regulatory standards. Additionally, outsourcing these operations helps streamline development timelines and reduces costs, enhancing overall project efficiency.
Europe vaccine contract manufacturing market will grow substantially over 2024-2032 due to stringent regulatory standards that necessitate specialized production capabilities. Increased investment in biopharmaceutical infrastructure and advancements in manufacturing technologies also play a role. Europe's focus on reducing dependence on non-EU production and enhancing supply chain resilience, particularly post-pandemic, drives demand. Additionally, growing public and private sector collaborations, alongside the need for scalable production solutions, further boost the region's contract manufacturing market.